ERBB2 and breast carcinoma: The high drug load (DAR 8) and bystander killing effect made T-DXd the first HER2-targeted therapy showing clinical benefit in HER2 low-expressing (IHC 1+ or IHC 2 + /FISH-) breast cancer [5,8–10].